UNSPSC 51161553: Proxyphylline

This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C10H14N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 13G1DMN4P0, chemically known as 3,7-dihydro-7-(2-hydroxypropyl)-1,3-dimethyl-1h-purine-2,6-dione but generally known as proxyphylline, which bears US NIH Compound Identifier 4977. European Medicines Agency schedules Proxyphylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10153MIG.

UNSPSC 51161553 Proxyphylline is a Commodity code covering branded and generic pharmaceutical active ingredients and finished pharmaceutical products purchased by state and local health agencies, corrections departments, and medicaid programs. State and local governments procure under this code to stock hospital formularies, correctional medical services, public health clinics, and shared pharmaceutical inventories through cooperative purchasing agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the issuing-body type most active under this code — multi-state cooperative purchasing vehicles that aggregate demand across participating state agencies and their subordinate local health systems, correctional facilities, and similar institutions. Individual state health departments and county health authorities also solicit directly, though cooperative vehicles dominate recent procurement volume because they leverage scale to negotiate manufacturer pricing and establish standing agreements with authorized pharmaceutical wholesalers.

Recent activity centers on the Upper Midwest and Pacific Northwest. MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products (solicitation S1070000015802, due March 26, 2026) is representative. The procurement establishes multiple contracts for manufacturers to supply finished pharmaceutical products through three designated wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awards effective July 1, 2026. Evaluation weights price competitiveness at 75 percent, with the remaining 25 percent split among fixed pricing terms (10 percent), EDI capability (5 percent), administrative compliance (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must certify cGMP and DSCSA compliance, maintain relationships with at least two of the three wholesalers, carry $5 million commercial general liability insurance per occurrence and $2 million network security liability, and ensure products carry expiration dates with a minimum six-month shelf life. The contract term runs two years for new responders with optional extensions, or amendments through June 30, 2028 for incumbents.